Eurobio Scientific Société anonyme (EPA:ALERS)
France · Delayed Price · Currency is EUR 25.10
0.00 (0.00%)
Oct 2, 2026, 5:35 PM CET
EPA:ALERS Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 172.26 | 168.6 | 154.56 | 130.65 | 152.9 | 185.32 |
| 172.26 | 168.6 | 154.56 | 130.65 | 152.9 | 185.32 | |
Revenue Growth | 6.28% | 9.08% | 18.30% | -14.56% | -17.50% | -2.04% |
Cost of Revenue | 93.2 | 91.75 | 82.99 | 73.16 | 81.66 | 85.91 |
Gross Profit | 79.06 | 76.85 | 71.57 | 57.49 | 71.24 | 99.41 |
Selling, General & Admin | 52.17 | 52.99 | 45.46 | 33.52 | 31 | 24.5 |
Research & Development | - | - | - | 5.91 | 3.47 | - |
Amortization of Goodwill & Intangibles | 3.78 | 3.78 | 3.75 | 7.92 | 5.9 | 4.79 |
Other Operating Expenses | 9.76 | 9.33 | 9.03 | - | - | - |
Operating Expenses | 65.71 | 66.1 | 58.24 | 47.35 | 40.37 | 29.29 |
Operating Income | 13.35 | 10.74 | 13.33 | 10.14 | 30.87 | 70.12 |
Interest Expense | -1.6 | -1.94 | -4.13 | -4.36 | -1.26 | -0.41 |
Interest & Investment Income | 0.01 | 0.03 | 1.48 | 1.12 | 0.04 | - |
Currency Exchange Gain (Loss) | 0.01 | -1.04 | 0.69 | 0.75 | 0.67 | 0.36 |
Other Non Operating Income (Expenses) | -0.38 | 0.19 | -3.71 | 0.77 | 0.04 | -0.05 |
EBT Excluding Unusual Items | 11.4 | 7.98 | 7.66 | 8.42 | 30.35 | 70.01 |
Gain (Loss) on Sale of Investments | -0.17 | -0.17 | - | - | - | 0.23 |
Other Unusual Items | - | - | -1.38 | -1.45 | -0.67 | 1.08 |
Pretax Income | 11.22 | 7.81 | 6.28 | 6.98 | 29.68 | 71.31 |
Income Tax Expense | 4.03 | 2.94 | 2.29 | 2.14 | 4.75 | 10.77 |
Earnings From Continuing Operations | 7.19 | 4.87 | 4 | 4.84 | 24.94 | 60.54 |
Net Income | 7.19 | 4.87 | 4 | 4.84 | 24.94 | 60.54 |
Net Income to Common | 7.19 | 4.87 | 4 | 4.84 | 24.94 | 60.54 |
Net Income Growth | 204.57% | 21.69% | -17.31% | -80.61% | -58.81% | -17.61% |
Shares Outstanding (Basic) | 10 | 10 | 10 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 11 | 11 | 11 |
Shares Change | -1.07% | - | -8.63% | -1.40% | 4.59% | -3.35% |
EPS (Basic) | 0.70 | 0.47 | 0.39 | 0.43 | 2.20 | 5.58 |
EPS (Diluted) | 0.70 | 0.47 | 0.39 | 0.43 | 2.20 | 5.57 |
EPS Growth | 209.44% | 20.51% | -9.30% | -80.44% | -60.53% | -14.70% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 6.36 | 6.28 | 13.45 | 22.71 | 40.24 | 64.07 |
Free Cash Flow Per Share | 0.62 | 0.61 | 1.31 | 2.02 | 3.54 | 5.89 |
Gross Margin | 45.90% | 45.58% | 46.30% | 44.00% | 46.59% | 53.64% |
Operating Margin | 7.75% | 6.37% | 8.63% | 7.76% | 20.19% | 37.84% |
Profit Margin | 4.18% | 2.89% | 2.59% | 3.70% | 16.31% | 32.67% |
Free Cash Flow Margin | 3.69% | 3.73% | 8.70% | 17.39% | 26.32% | 34.57% |
EBITDA | 22.78 | 22.44 | 27.39 | 23.29 | 40.5 | 77.98 |
EBITDA Margin | 13.23% | 13.31% | 17.72% | 17.82% | 26.49% | 42.08% |
D&A For EBITDA | 9.43 | 11.7 | 14.06 | 13.15 | 9.63 | 7.87 |
EBIT | 13.35 | 10.74 | 13.33 | 10.14 | 30.87 | 70.12 |
EBIT Margin | 7.75% | 6.37% | 8.63% | 7.76% | 20.19% | 37.84% |
Effective Tax Rate | 35.89% | 37.67% | 36.38% | 30.70% | 15.99% | 15.10% |
Revenue as Reported | - | - | - | 130.65 | 152.9 | 185.32 |